{"id":1790,"date":"2021-11-15T23:57:56","date_gmt":"2021-11-15T23:57:56","guid":{"rendered":"https:\/\/jewelryon.com\/?p=1790"},"modified":"2021-11-30T17:27:34","modified_gmt":"2021-11-30T17:27:34","slug":"pfizer-whistleblower-sinks-vaccine-trial-integrity-mercola","status":"publish","type":"post","link":"https:\/\/jewelryon.com\/?p=1790","title":{"rendered":"Pfizer Whistleblower Sinks Vaccine Trial Integrity &#8211; Mercola"},"content":{"rendered":"<div style=\"width: 640px;\" class=\"wp-video\"><video class=\"wp-video-shortcode\" id=\"video-1790-1\" width=\"640\" height=\"360\" preload=\"metadata\" controls=\"controls\"><source type=\"video\/mp4\" src=\"https:\/\/oh17.com\/video\/Pfizer-Whistleblower-Sinks-Vaccine-Trial-Integrity.mp4?_=1\" \/><a href=\"https:\/\/oh17.com\/video\/Pfizer-Whistleblower-Sinks-Vaccine-Trial-Integrity.mp4\">https:\/\/oh17.com\/video\/Pfizer-Whistleblower-Sinks-Vaccine-Trial-Integrity.mp4<\/a><\/video><\/div>\n<p><a href=\"https:\/\/oh17.com\/video\/pfizer-whistleblower-scientific-fraud-mercola.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">READ PDF<\/a><\/p>\n<div id=\"bcr_UpdPnlStory\">\n<div id=\"bcr_pnlStoryAtAGlance\" class=\"story-glance\" data-swiftype-name=\"saag\" data-swiftype-type=\"text\">\n<div class=\"story-highlights\">\n<h3 id=\"expanderHead\" data-jsid=\"expanderHead\">STORY AT-A-GLANCE<\/h3>\n<div id=\"expanderContent\" data-jsid=\"expanderContent\">\n<ul>\n<li><span id=\"bcr_rptStory_cslStory_0\">According to a whistleblower who worked on Pfizer\u2019s Phase 3 COVID jab trial, data were falsified, patients were unblinded, the company hired poorly trained people to administer the injections, and follow-up on reported side effects lagged way behind<\/span><\/li>\n<li><span id=\"bcr_rptStory_cslStory_1\">Brook Jackson was the regional director of Ventavia Research Group, a research organization charged with testing Pfizer\u2019s COVID jab at several sites in Texas. Jackson repeatedly \u201cinformed her superiors of poor laboratory management, patient safety concerns, and data integrity issues,\u201d and when her concerns were ignored, she finally filed a complaint with the U.S. Food and Drug Administration<\/span><\/li>\n<li><span id=\"bcr_rptStory_cslStory_2\">The FDA did not follow up on her complaint. Ventavia was not one of the nine trial locations audited, and Pfizer did not bring any of those issues up when applying for emergency use authorization for its COVID shot<\/span><\/li>\n<li><span id=\"bcr_rptStory_cslStory_3\">Documentation shared by Jackson shows a Ventavia executive had identified three site staff members who had falsified data<\/span><\/li>\n<li><span id=\"bcr_rptStory_cslStory_4\">After being notified of Jackson\u2019s complaints, Pfizer contracted Ventavia to conduct four additional trials \u2014 one for COVID shots in children and young adults, one for the COVID jab in pregnant women, a booster shot trial, and an RSV vaccine trial<\/span><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div id=\"bodytext\" class=\"bodytextdiv\" data-swiftype-name=\"postbody\" data-swiftype-type=\"text\">\n<p>Yet again, mainstream media have completely ignored what should have been front-page news. According to a whistleblower who worked on Pfizer\u2019s Phase 3 COVID jab trial in the fall of 2020, data were falsified, patients were unblinded, the company hired poorly trained people to administer the injections, and follow-up on reported side effects lagged way behind.<\/p>\n<p>What makes the media\u2019s silence all the more remarkable is that this revelation was published in The British Medical Journal. Paul Thacker, investigative journalist for The BMJ, writes in his November 2, 2021, report:<sup><span id=\"edn1\" data-hash=\"#ednref1\">1<\/span><\/sup><\/p>\n<blockquote><p><em>\u201cRevelations of poor practices at a contract research company helping to carry out Pfizer\u2019s pivotal covid-19 vaccine trial raise questions about data integrity and regulatory oversight\u00a0&#8230;<\/em><\/p><\/blockquote>\n<blockquote><p><em>[F]or researchers who were testing Pfizer\u2019s vaccine at several sites in Texas during that autumn, speed may have come at the cost of data integrity and patient safety &#8230; Staff who conducted quality control checks were overwhelmed by the volume of problems they were finding.\u201d<\/em><\/p><\/blockquote>\n<p>As noted by Bill Bruckner for transparimed.org:<sup><span id=\"edn2\" data-hash=\"#ednref2\">2<\/span><\/sup><\/p>\n<blockquote><p><em>\u201cEditors\u2019 widespread failure to pick up on the story is deeply problematic. First and foremost, it lets the U.S. Food and Drug Administration off the hook for what appear to be severe lapses in regulatory oversight over this trial &#8230; Where are the media outlets questioning the FDA about its oversight processes? Where are the politicians calling for an enquiry? &#8230;<\/em><\/p><\/blockquote>\n<blockquote><p><em>Second, it lets Pfizer off the hook for apparently failing to adequately oversee the operations of its subcontractor &#8230; Where are the media outlets questioning Pfizer about its oversight and quality assurance processes? &#8230;<\/em><\/p><\/blockquote>\n<blockquote>\n<div class=\"MidProductAd\"><\/div>\n<p><em>Third, it undermines confidence in democratic institutions and public health bodies because it gives citizens &#8230; the impression that mainstream media are deliberately ignoring a big story in order to avoid fueling vaccine hesitancy.\u201d<\/em><\/p><\/blockquote>\n<p>So far, this story has been largely confined to the alternative news media. You\u2019ll find a selection of video reports covering the whistleblower\u2019s testimony in the sections below.<\/p>\n<h2>Research Organization Falsified Data in Pfizer Trial<\/h2>\n<div class=\"video-rwd\">\n<figure class=\"op-interactive aspect-ratio\"><iframe id=\"iFrameResizer0\" class=\" mlazyloaded\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/AjHoca9wgoY?wmode=transparent&amp;rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" scrolling=\"no\" allowfullscreen=\"allowfullscreen\" data-mlazyload-src=\"https:\/\/www.youtube.com\/embed\/AjHoca9wgoY?wmode=transparent&amp;rel=0\"><\/iframe><\/figure>\n<\/div>\n<p>The whistleblower in question is Brook Jackson, a former regional director of Ventavia Research Group, a research organization charged with testing Pfizer\u2019s COVID jab at several sites in Texas.<\/p>\n<p>Jackson repeatedly \u201cinformed her superiors of poor laboratory management, patient safety concerns and data integrity issues,\u201d Thacker writes, and when her concerns were ignored, she finally called the U.S. Food and Drug Administration and filed a complaint via email.<\/p>\n<p>Jackson was fired later that day after just two weeks on the job. According to her separation letter, management decided she was \u201cnot a good fit\u201d for the company after all. She has provided The BMJ with \u201cdozens of internal company documents, photos, audio recordings and emails\u201d proving her concerns were valid. According to Jackson, this was the first time she\u2019d ever been fired in her 20-year career as a clinical research coordinator. Thacker explains:<sup><span id=\"edn3\" data-hash=\"#ednref3\">3<\/span><\/sup><\/p>\n<blockquote><p><em>\u201cJackson was a trained clinical trial auditor who previously held a director of operations position and came to Ventavia with more than 15 years\u2019 experience in clinical research coordination and management.<\/em><\/p><\/blockquote>\n<blockquote><p><em>Exasperated that Ventavia was not dealing with the problems, Jackson documented several matters late one night, taking photos on her mobile phone. One photo, provided to The BMJ, showed needles discarded in a plastic biohazard bag instead of a sharps container box.<\/em><\/p><\/blockquote>\n<blockquote><p><em>Another showed vaccine packaging materials with trial participants\u2019 identification numbers written on them left out in the open, potentially unblinding participants &#8230; Jackson told The BMJ that drug assignment confirmation printouts were being left in participants\u2019 charts, accessible to blinded personnel &#8230;<\/em><\/p><\/blockquote>\n<blockquote><p><em>In a recording of a meeting in late September 2020 between Jackson and two directors a Ventavia executive can be heard explaining that the company wasn\u2019t able to quantify the types and number of errors they were finding when examining the trial paperwork for quality control. \u2018In my mind, it\u2019s something new every day,\u2019 a Ventavia executive says. \u2018We know that it\u2019s significant.\u2019<\/em><\/p><\/blockquote>\n<blockquote><p><em>Ventavia was not keeping up with data entry queries, shows an email sent by ICON, the contract research organization with which Pfizer partnered on the trial. ICON reminded Ventavia in a September 2020 email: \u2018The expectation for this study is that all queries are addressed within 24hrs.\u2019<\/em><\/p><\/blockquote>\n<blockquote><p><em>ICON then highlighted over 100 outstanding queries older than three days in yellow. Examples included two individuals for which \u2018Subject has reported with Severe symptoms\/reactions \u2026 Per protocol, subjects experiencing Grade 3 local reactions should be contacted. Please confirm if an UNPLANNED CONTACT was made and update the corresponding form as appropriate.\u2019<\/em><\/p><\/blockquote>\n<blockquote><p><em>According to the trial protocol a telephone contact should have occurred \u2018to ascertain further details and determine whether a site visit is clinically indicated.\u2019 Documents show that problems had been going on for weeks.<\/em><\/p><\/blockquote>\n<blockquote><p><em>In a list of \u2018action items\u2019 circulated among Ventavia leaders in early August 2020, shortly after the trial began and before Jackson\u2019s hiring, a Ventavia executive identified three site staff members with whom to \u2018Go over e-diary issue\/falsifying data, etc.\u2019 One of them was \u2018verbally counseled for changing data and not noting late entry,\u2019 a note indicates.\u201d<\/em><\/p><\/blockquote>\n<div class=\"productad\"><\/div>\n<h2>FDA Ignored Whistleblower Concerns<\/h2>\n<p>In her complaint to the FDA, Jackson listed a dozen incidents of concern, including the following:<\/p>\n<ul>\n<li>Participants were not monitored by clinical staff after receiving the shot<\/li>\n<li>Patients who experienced adverse effects were not promptly evaluated<\/li>\n<li>Protocol deviations were not being reported<\/li>\n<li>The Pfizer injection vials were stored at improper temperatures<\/li>\n<li>Laboratory specimens were mislabeled<\/li>\n<\/ul>\n<p>Not a single one of the problems Jackson raised in her complaint to the FDA were noted or addressed in Pfizer\u2019s briefing document submitted to the FDA\u2019s advisory committee meeting December 20, 2020, when its emergency use authorization application was reviewed.<\/p>\n<p>The FDA went ahead, granting the Pfizer jab emergency use authorization the very next day, despite being in receipt of Jackson\u2019s complaint, which ought to have put the brakes on the FDA\u2019s authorization. At bare minimum, they should have investigated the matter before proceeding.<\/p>\n<p>What\u2019s more, the FDA\u2019s summary of its inspections of the Pfizer trial, published in August 2021, revealed the agency only inspected nine of the 153 trial sites, and Ventavia was not one of them. The complaint also appears to have been ignored when the FDA granted full approval to Comirnaty, Pfizer\/BioNTech\u2019s COVID shot that is not yet available.<\/p>\n<p>Pfizer is also in on the cover-up. Shortly after Jackson\u2019s firing, Pfizer was notified of the problems she\u2019d raised. Despite that, Pfizer has since then contracted Ventavia to conduct no less than four additional trials \u2014 one for COVID shots in children and young adults, one for the COVID jab in pregnant women, a booster shot trial, and an RSV vaccine trial.<\/p>\n<p>So, clearly, Pfizer is not opposed to contractors falsifying data or otherwise undermining the integrity of the trials. That alone is a fiery indictment against Pfizer.<\/p>\n<p>They can feign ignorance and proclaim to adhere to \u201cthe highest scientific, ethical and clinical standards\u201d<sup><span id=\"edn4\" data-hash=\"#ednref4\">4<\/span><\/sup>\u00a0all they want. Those are just words which, unless backed by consistent action, are completely meaningless. Behind the scenes, they\u2019re clearly well-aware that their trials are resting on fraudulent foundations.<\/p>\n<h2>Pfizer Trial Described as a \u2018Crazy Mess\u2019<\/h2>\n<div class=\"video-rwd\">\n<figure class=\"op-interactive aspect-ratio\"><iframe id=\"iFrameResizer1\" class=\" mlazyloaded\" title=\"YouTube video player\" src=\"https:\/\/www.youtube.com\/embed\/8XscMyBs01U?wmode=transparent&amp;rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" scrolling=\"no\" allowfullscreen=\"allowfullscreen\" data-mlazyload-src=\"https:\/\/www.youtube.com\/embed\/8XscMyBs01U?wmode=transparent&amp;rel=0\"><\/iframe><\/figure>\n<\/div>\n<p>Jackson wasn\u2019t the only employee to get sacked from Ventavia after raising concerns about the integrity of the Pfizer trial. Thacker writes:<sup><span id=\"edn5\" data-hash=\"#ednref5\">5<\/span><\/sup><\/p>\n<blockquote><p><em>\u201cIn recent months Jackson has reconnected with several former Ventavia employees who all left or were fired from the company. One of them was one of the officials who had taken part in the late September meeting. In a text message sent in June the former official apologized, saying that \u2018everything that you complained about was spot on.\u2019<\/em><\/p><\/blockquote>\n<blockquote><p><em>Two former Ventavia employees spoke to The BMJ anonymously for fear of reprisal and loss of job prospects in the tightly knit research community. Both confirmed broad aspects of Jackson\u2019s complaint.<\/em><\/p><\/blockquote>\n<blockquote><p><em>One said that she had worked on over four dozen clinical trials in her career, including many large trials, but had never experienced such a \u2018helter skelter\u2019 work environment as with Ventavia on Pfizer\u2019s trial. \u2018I\u2019ve never had to do what they were asking me to do, ever,\u2019 she told The BMJ. \u2018It just seemed like something a little different from normal \u2014 the things that were allowed and expected\u2019 &#8230;<\/em><\/p><\/blockquote>\n<blockquote><p><em>After Jackson left the company problems persisted at Ventavia, this employee said. In several cases Ventavia lacked enough employees to swab all trial participants who reported COVID-like symptoms, to test for infection. Laboratory confirmed symptomatic COVID-19 was the trial\u2019s primary endpoint, the employee noted.<\/em><\/p><\/blockquote>\n<blockquote><p><em>(An FDA review memorandum released in August this year states that across the full trial swabs were not taken from 477 people with suspected cases of symptomatic COVID-19.) \u2018I don\u2019t think it was good clean data,\u2019 the employee said of the data Ventavia generated for the Pfizer trial. \u2018It\u2019s a crazy mess.\u2019\u201d<\/em><\/p><\/blockquote>\n<p>Such statements clearly fly in the face of statements made by world leaders, health authorities and the mainstream media. Most, like federal health minister for Australia, Greg Hunt, have claimed the COVID shots have undergone \u201crigorous, independent testing\u201d to ensure they\u2019re \u201csafe, effective and manufactured to a high standard.\u201d<sup><span id=\"edn6\" data-hash=\"#ednref6\">6<\/span><\/sup><\/p>\n<p>Nothing we know so far supports such a conclusion. The testing has been far from rigorous and has not been independently verified.<\/p>\n<p>Vaccine Adverse Events Reporting System (VAERS) data show they\u2019re shockingly far from safe; real-world data show effectiveness wanes within a handful of months while leaving you more susceptible to SARS-CoV-2 variants and other infections; and manufacturing standards have also been shown lacking, as a variety of foreign contaminants have been found in the vials.<sup><span id=\"edn7\" data-hash=\"#ednref7\">7<\/span><\/sup><\/p>\n<h2>Media Are Manipulated by Pfizer<\/h2>\n<figure class=\"center-img\"><img decoding=\"async\" class=\" mlazyloaded\" src=\"https:\/\/media.mercola.com\/ImageServer\/public\/2021\/November\/propaganda-from-a-pharmaceutical-company.jpg\" alt=\"propaganda from a pharmaceutical company\" data-mlazyload-src=\"https:\/\/media.mercola.com\/ImageServer\/public\/2021\/November\/propaganda-from-a-pharmaceutical-company.jpg\" \/><\/figure>\n<p>One of the reasons why English- and German-speaking legacy media have completely ignored this whistleblower testimony is probably because Pfizer has such a dominating influence over them. Thacker told blogger Maryanne Demasi, Ph.D.,<sup><span id=\"edn8\" data-hash=\"#ednref8\">8<\/span><\/sup>\u00a0\u201cPfizer has such a huge PR machine, they have basically captured the media, they\u2019ve hypnotized the media.\u201d<\/p>\n<p>Pfizer\u2019s PR department is also hard at work trying to hypnotize the public. The TV ad above is perhaps one of the most offensive. In it, Pfizer brainwashes young children into thinking that getting the COVID shot will make them superheroes. Never mind the fact that getting the shot could kill or permanently injure them.<\/p>\n<h2>You Cannot \u2018Follow the Science\u2019 if There Are No Data<\/h2>\n<p>The video at the top of this article is a short extract from a November 2, 2021, meeting organized by Sen. Ron Johnson, during which associate editor of The BMJ, Peter Doshi, Ph.D., reviewed some of the many concerns experts have about the integrity of the COVID jab data.<\/p>\n<p>He points out that Pfizer\u2019s raw trial data will not be made available until May 2025. So far, Pfizer has refused to release any of its raw data to independent investigators and, without that, there\u2019s no possible way to confirm that what Pfizer is claiming is actually true and correct.<\/p>\n<aside class=\"takeaway tamiddle\">Without data, it\u2019s not science. ~ Peter Doshi, Ph.D., associate editor of The British Medical Journal<\/aside>\n<p>In other words, we\u2019re expected to simply take the word of a company that has earned a top spot on the list of white collar criminals; a company that in 2009 was fined a record-breaking $2.3 billion in fines for fraudulent marketing and health care fraud.<sup><span id=\"edn9\" data-hash=\"#ednref9\">9<\/span><\/sup>\u00a0Press releases are not science. They\u2019re marketing. Without the raw data, we have no science upon which to base our decisions about the COVID shot.<\/p>\n<p>As noted by Dr. Robert Kaplan from Stanford\u2019s School of Medicine Clinical Excellence Research Centre, who also spoke at the meeting:<\/p>\n<blockquote><p><em>\u201cThe evidence we have comes from highly curated, industry-controlled press releases and journal publications. We are making big decisions based on limited, highly selected evidence. A compromised scientific process will lead to poor decisions, and it may set a bad precedent.\u201d<\/em><\/p><\/blockquote>\n<p>Doshi stresses how utterly unscientific a process we\u2019re now following. He also points out that doctors have an ethical duty to not recommend a treatment for which they have no data. Quoting from a 2020 article he co-wrote:<sup><span id=\"edn10\" data-hash=\"#ednref10\">10<\/span><\/sup><\/p>\n<blockquote><p><em>\u201cData transparency is not a \u2018nice to have.\u2019 Claims made without access to the data \u2014 whether appearing in peer reviewed publications or in preprints without peer review \u2014 are not scientific claims.<\/em><\/p><\/blockquote>\n<blockquote><p><em>Products can be marketed without access to the data, but doctors and professional societies should publicly state that, without complete data transparency, they will refuse to endorse COVID-19 products as being based on science.\u201d<\/em><\/p><\/blockquote>\n<p>\u201cThe point I am trying to make is very simple,\u201d Doshi said. \u201cThe data from COVID vaccines are not available and won\u2019t be available for years. Yet, we are not just \u2018asking\u2019 but \u2018mandating\u2019 millions of people to take these vaccines &#8230; Without data, it\u2019s not science.\u201d<\/p>\n<h2>Regulatory Agencies Are Designed to Fail<\/h2>\n<p>We\u2019ve known the FDA is a captured agency for at least a decade. None of the issues we\u2019re now seeing are exactly new. We\u2019re now getting a close-up view of just how dangerous the incestuous relationship between the FDA and Big Pharma really is.<\/p>\n<p>Americans are dying from COVID jab injuries at unprecedented record rates, and the FDA is completely ignoring it. Instead, it continues to push for more jabs, more injuries and more deaths. It\u2019s complicit in causing avoidable deaths rather than protecting public health. That\u2019s the price we\u2019re now paying for not cleaning up the agency and sealing the revolving door between regulators and industry earlier.<\/p>\n<p>In \u201cDesigned to Fail: Why Regulatory Agencies Don\u2019t Work,\u201d<sup><span id=\"edn11\" data-hash=\"#ednref11\">11<\/span><\/sup>\u00a0published in May 2012 \u2014 nearly a decade ago \u2014 William Sanjour discussed the failures of regulatory reform. He points out that the reason reforms don\u2019t work is because they keep reforming in the wrong direction:<\/p>\n<blockquote><p><em>\u201c&#8230; as a result of the recent catastrophic failures of regulatory agencies, politicians and pundits are talking about the same old \u2018Regulatory Reform\u2019 again. \u2018Fill the regulatory agencies with honest people who won\u2019t cave in to special interests.\u2019 \u2018Give them more money, more authority and more people.\u2019<\/em><\/p><\/blockquote>\n<blockquote><p><em>But my experience has shown that by concentrating all legislative, executive and judiciary authority in one regulatory agency just makes it easier for it to be corrupted by the industries it regulates.<\/em><\/p><\/blockquote>\n<blockquote><p><em>I worked for the U.S. Environmental Protection agency for 30 years and lived through many cycles of \u2018Regulatory Reform,\u2019 doing the same \u2018reforms\u2019 over and over again and expecting different results.<\/em><\/p><\/blockquote>\n<blockquote><p><em>I\u2019ve learned that the way to achieve true regulatory reform is to give regulatory agencies less money, less authority, fewer people but more intelligent regulations. The theme of this article is that by dispersing regulatory authority, rather than concentrating it, we would make corruption more difficult and facilitate more sensible regulation.\u201d<\/em><\/p><\/blockquote>\n<p>Sanjour points out that regulators being captured by the parties they\u2019re supposed to regulate is far more dangerous than having no regulatory agencies at all, because \u201ccapture gives industry the power of government.\u201d Can there be any doubt that the FDA, as an agency captured by Big Pharma in general and Pfizer in particular, now wields power over the U.S. government?<\/p>\n<blockquote><p><em>\u201cFrom my own experience with the U.S. EPA, even if an inspector finds a violation, this only triggers a lengthy complex process with many levels of warning, review, appeal, negotiation, and adjudication before any action is taken (or, more often, avoided),\u201d<\/em>\u00a0Sanjour writes.<sup><span id=\"edn12\" data-hash=\"#ednref12\">12<\/span><\/sup><\/p><\/blockquote>\n<blockquote><p><em>\u201cSee the labyrinthine flow chart<sup><span id=\"edn13\" data-hash=\"#ednref13\">13<\/span><\/sup>\u00a0for an example of an agency enforcement procedure. It resembles a game of \u2018chutes and ladders.\u2019 Compare this with what happens when you park under a \u2018No Parking\u2019 sign. A policeman writes a ticket, and you can either pay the fine or tell it to the judge.<\/em><\/p><\/blockquote>\n<blockquote><p><em>If the EPA wrote the rules for parking violations, the officer would first have to determine if there were sufficient legal parking available at a reasonable cost and at a reasonable distance, and would then have to stand by the car and wait until the owner showed up so that he could negotiate a settlement agreement.\u201d<\/em><\/p><\/blockquote>\n<h2>Regulatory Complexity Intentionally Hides Loopholes<\/h2>\n<p>Even more disturbing, Sanjour reveals that, when he was writing regulations for the EPA, he was \u201ctold on more than one occasion to make sure I put in enough loopholes. The purpose of the complexity is to hide the loopholes.\u201d Sanjour went on to explain:<\/p>\n<blockquote><p><em>\u201cRegulatory agencies are created by Congress in order to control some powerful forces in society (usually corporations), which benefit society but which are also prone to abuse their power. The purpose of a regulatory agency is to allow the flow of benefits while straining out the abuse.<\/em><\/p><\/blockquote>\n<blockquote><p><em>In order to do this, Congress gives administrators of regulatory agencies broad discretionary power to write regulations for industries for which they are responsible. The flaw in the system is that the administrator is appointed by the president &#8230; Thus any discretionary authority given to a regulatory agency administrator is, in fact, given to the president of the United States to be used as the president sees fit &#8230;<\/em><\/p><\/blockquote>\n<blockquote><p><em>[R]egulatory agencies, by their very nature, can do little that doesn\u2019t adversely affect business, especially big and influential business, and this disturbs a president\u2019s repose.<\/em><\/p><\/blockquote>\n<blockquote><p><em>The EPA, for instance, cannot write regulations governing the petroleum industry without the oil companies going to the White House screaming \u2018energy crisis!\u2019 &#8230; When the FDA wants to thoroughly evaluate a new drug, the pharmaceutical company lets loose a public relations barrage about how the bureaucratic delays are costing lives.<\/em><\/p><\/blockquote>\n<blockquote><p><em>Regulatory agency employees soon learn that drafting and implementing rules for big corporations means making enemies of powerful and influential people. They learn to be \u2018team players,\u2019 an ethic that permeates the entire agency without ever being transmitted through written or even oral instructions.<\/em><\/p><\/blockquote>\n<blockquote><p><em>People who like to get things done, who need to see concrete results for their efforts, don\u2019t last long. They don\u2019t necessarily get fired, but they don\u2019t advance either; their responsibilities are transferred to others, and they often leave the agency in disgust. The people who get ahead are those clever ones with a talent for procrastination, obfuscation, and coming up with superficially plausible reasons for accomplishing nothing.\u201d<\/em><\/p><\/blockquote>\n<h2>How Do We Fix It?<\/h2>\n<p>The question staring us in the face now is, how do we fix these regulatory agencies so that they can operate for the benefit of the public rather than private for-profit interests?<\/p>\n<p>\u201cThe reason salaried government regulators can be corrupted is that writing and enforcing effective regulations is not their No. 1 priority,\u201d Sanjour noted. \u201cTheir main objective is keeping their job and advancing their careers.\u201d Industries, meanwhile, believe that pressuring corrupt officials is the only way to protect their business. The answer, Sanjour suggests, is:<\/p>\n<blockquote><p><em>\u201c\u2026 to remove discretionary judgment from the hands of the regulatory bureaucracy and place it in hands less susceptible to industry influence. The first thing I would suggest is to make use of people or institutions who have a vested interest in effective regulation as strong or stronger than the regulated community.\u201d<\/em><\/p><\/blockquote>\n<p>Sanjour cites research showing that, by far, whistleblowers \u2014 who risk their jobs by speaking out \u2014 are the No. 1 fraud detection group, responsible for 19% of frauds being brought to light. The U.S. Securities and Exchange Commission, meanwhile, which exists to uncover corporate fraud, was responsible for just 7%.<\/p>\n<p>So, one way we could improve the system is by issuing monetary rewards to corporate whistleblowers. \u201cMonetary rewards for whistleblowers pay benefits far in excess of the cost when compared with hired regulatory bureaucrats,\u201d Sanjour notes. Insurance companies can also play an important role, as they are far less likely to overlook safety shortcuts that can result in disaster. An example given by Sanjour is the BP oil spill:<\/p>\n<blockquote><p><em>\u201cBP has admitted, between 2005 and 2010, to breaking U.S. environmental and safety laws and committing outright fraud and paid $373 million in fines. Between June 2007 and February 2010, BP refineries in Texas and Ohio accounted for 97% of the \u2018egregious, willful\u2019 violations handed out by the U.S. Occupational Safety and Health Administration. Yet none of this resulted in any oversight of the Deepwater Horizon oil rig that blew up &#8230;<\/em><\/p><\/blockquote>\n<blockquote><p><em>If BP had been required to carry a $10 billion insurance policy for an oil spill, I\u2019m sure the insurance company would not have allowed the penny-pinching short cuts that the paid regulators allowed. If the laws are written intelligently, insurance companies can be a significant instrument for regulation.\u201d<\/em><\/p><\/blockquote>\n<p>A third group that makes for a far better fraud detection system than federal regulators is the public. Organizations such as Citizens for Health and Environmental Justice teaches citizens how to get involved in the enforcement of regulations, and even more can be done in that regard.<\/p>\n<p>For example, the EPA could sponsor civilian testing and equip citizens living in polluted areas with resources to conduct their own testing and report back if toxic exposures are found. Sanjour continues:<sup><span id=\"edn14\" data-hash=\"#ednref14\">14<\/span><\/sup><\/p>\n<blockquote><p><em>\u201cA second reform I would suggest for removing discretionary authority from the regulatory bureaucracy is to make the rules as simple as possible and to place all appellate functions and consent agreements into the hands of the law courts, just as in our traffic cop example.<\/em><\/p><\/blockquote>\n<blockquote><p><em>This could be judicial courts or administrative law courts. Anything to take the discretionary authority away from the people who write and enforce the rules and provide one more barrier to industry influence.\u201d<\/em><\/p><\/blockquote>\n<h2>We Need to Return to the Constitution<\/h2>\n<p>To do any or all of that, we first need to reorganize our regulatory agencies in accordance with the U.S. Constitution. As explained by Sanjour, the U.S. has three branches of government: the legislative, executive and judicial branches. However, when regulatory agencies were formed, we diverted from this structure.<\/p>\n<p>Regulations are a type of laws, and as such they should come from the legislative branch. But regulatory agencies are part of the executive branch. Judicial functions have also been usurped by regulatory agencies, and hence the executive branch.<\/p>\n<blockquote><p><em>\u201cThus, despite the wishes of the Founding Fathers, the executive branch now includes a great many regulatory agencies whose functions span all three branches of government. A large part of the corruption and inefficiency noted above flows from this fact,\u201d<\/em>\u00a0Sanjour notes.<\/p><\/blockquote>\n<p>While making changes such as those proposed by Sanjour sounds simple enough, the political pushback would be enormous, and would have to be broken through, somehow. Legally, however, it would be a reasonably simple affair.<\/p>\n<p>All Congress would need to do is amend the law such that the agency administrator is stripped of its authority to write rules and implement the law. That authority would then be transferred to another agency, the administrator of which would be appointed by Congress, not the president.<\/p>\n<p>\u201cNote that these are all paper changes. They do not require any relocation, new buildings, new hires, etc. The functions all currently exist. They are merely rearranged,\u201d Sanjour says.<\/p>\n<p>At present, we can no longer overlook the FDA\u2019s corruption. It\u2019s costing too many lives. They have completely abandoned any semblance of working for the public good. How we get rid of them and fix the problem will become an increasingly pressing question as we move forward.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>https:\/\/oh17.com\/video\/Pfizer-Whistleblower-Sinks-Vaccine-Trial-Integrity.mp4 READ PDF STORY AT-A-GLANCE According to a whistleblower who worked on Pfizer\u2019s Phase 3 COVID jab trial, data were falsified, patients were unblinded, the company hired poorly trained people to administer the injections, and follow-up on reported side effects lagged way behind Brook Jackson was the regional director of Ventavia Research Group, a research&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1790","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jewelryon.com\/index.php?rest_route=\/wp\/v2\/posts\/1790","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jewelryon.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jewelryon.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jewelryon.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jewelryon.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1790"}],"version-history":[{"count":0,"href":"https:\/\/jewelryon.com\/index.php?rest_route=\/wp\/v2\/posts\/1790\/revisions"}],"wp:attachment":[{"href":"https:\/\/jewelryon.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1790"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jewelryon.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1790"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jewelryon.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1790"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}